<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422019</url>
  </required_header>
  <id_info>
    <org_study_id>20060100</org_study_id>
    <nct_id>NCT00422019</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma</brief_title>
  <official_title>A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients
      with Advanced Renal Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the objective response rate in subjects with advanced renal cell carcinoma receiving AMG 102 treatment</measure>
    <time_frame>9 weeks from first dose of AMG 102</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the overall survival and progression free survival rates in this population</measure>
    <time_frame>8 week intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of response and time to response in this population</measure>
    <time_frame>treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics of AMG 102 in subjects with advanced renal cell carcinoma</measure>
    <time_frame>Weeks 1, 5, and 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety profile of AMG 102 in subjects with advanced renal cell carcinoma</measure>
    <time_frame>entire study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>AMG 102 at 20 mg/kg Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 102 at 10 mg/kg Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102 at 10 mg/kg</intervention_name>
    <description>AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks</description>
    <arm_group_label>AMG 102 at 10 mg/kg Dose Level</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102 at 20 mg/kg</intervention_name>
    <description>AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks</description>
    <arm_group_label>AMG 102 at 20 mg/kg Dose Level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented histologically confirmed advanced or metastatic renal cell carcinoma with
             the primary tumor in place or following nephrectomy

          -  measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques (CT or MRI) or ≥ 10 mm by spiral CT scan

          -  no more than 3 relapses (or prior systemic treatments)

          -  unable to receive or failed prior therapy with vascular endothelial growth factor
             (VEGF) binding agents or VEGF receptor tyrosine kinase inhibitors or other
             multi-kinase inhibitors

          -  tissue blocks or tissue sections from initial or upon diagnosis of advanced metastatic
             disease are available for submission to the central laboratory within approximately 4
             weeks after enrollment or approval is granted by the sponsor (upon receipt of
             justification why the sample is not available)

          -  age ≥ 18 years

          -  ECOG performance status of 0-2

          -  hemoglobin concentration ≥ 9 g/dL

          -  absolute neutrophil count ≥ 1.5 x 10(9th)/L

          -  corrected serum calcium ≤ 10 mg/dL

          -  either serum creatinine &lt; 2.0 x upper limit of normal OR creatinine clearance &gt; 40
             mL/min

          -  alanine aminotransferase ≤ 2.5 times upper limit of normal or &lt; 5.0 x ULN if the
             subject has documented liver metastasis or primary hepatic neoplasm

          -  serum total bilirubin ≤ 2.5 times upper limit of normal

          -  before any study-specific procedure, the appropriate written informed consent must be
             obtained

        Exclusion Criteria:

          -  active brain metastases; brain metastases allowed provided they have been treated with
             surgery and/or radiation therapy and show no evidence of progression on cerebral CT or
             MRI scan 2 months following surgery and/or radiation therapy

          -  concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,
             congestive cardiac failure, myocardial infarction within 6 months before enrollment)
             that could compromise participation in the study

          -  documented history of human immunodeficiency virus infection

          -  documented history of viral chronic hepatitis

          -  received biologic, small molecule, immunotherapy, chemotherapy, radiotherapy or other
             agents to treat renal cancer within 28 days before enrollment

          -  treated previously with c-Met or HGF targeted therapy

          -  concurrent or prior (within 7 days before enrollment) anticoagulation therapy, except:

               -  Use of low-dose warfarin (&lt; 2 mg/day) for prophylaxis against central venous
                  catheter thrombosis or

               -  Use of low molecular weight heparins (LMWH, e.g., enoxaparin sodium [Lovenox] and
                  unfractionated heparin for prophylaxis against central venous catheter thrombosis
                  is allowed

          -  concurrent use of hormones or other chemotherapeutic agents except for steroids given
             for adrenal failure and hormones administered for non-disease-related conditions (eg,
             insulin for diabetes); except for non-cancer reasons

          -  concurrent palliative or therapeutic radiation therapy

          -  currently enrolled in or has not yet completed at least 30 days since ending other
             investigational device or therapy, or subject is receiving other investigational
             agent(s)

          -  active infection requiring treatment within 1 week before enrollment

          -  undergone major surgery within 4 weeks before enrollment or recovering from prior
             surgery

          -  past or current history of another neoplasm, except for curatively treated
             non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid
             cancer with no known active disease present and no curative treatment administered for
             the last 3 years

          -  known allergy or sensitivity to any of the excipients in the investigational product
             to be administered

          -  pregnant or is breast feeding

          -  not consenting to use adequate contraceptive precautions during the course of the
             study and for 6 months after the last administration of investigational product:

               -  female subjects who are not post-menopausal (no menstrual period for a minimum of
                  12 months at study entry) or documented surgically sterile will not be bound to
                  this exclusion

          -  previously treated with AMG 102

          -  previously enrolled into this study

          -  will not be available for follow-up assessments

          -  has other disorders that compromises the ability of the subject to give written
             informed consent and/or comply with study procedures

          -  unable to begin protocol specified treatment within 3 days after enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Schöffski P, Garcia J, Stadler W, Gil T, Jonasch E, Tagawa S, Kabbinavar F.A phase 2 study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.Journal-004247;2010 Dec 15; 1-8</citation>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <disposition_first_submitted>March 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 10, 2015</disposition_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydrotachysterol</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

